Drug
Glecaprevir and Pibrentasvir
Glecaprevir and Pibrentasvir is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(67%)
Phase Distribution
Ph phase_4
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 4
Trials by Phase
Phase 42 (100.0%)
Trials by Status
completed133%
terminated267%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_4
HCV Test and Treat Utilizing Simplified HCV Patient Education
NCT05582681
terminatedphase_4
QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir
NCT04515797
completed
eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
NCT04047680
Clinical Trials (3)
Showing 3 of 3 trials
NCT05582681Phase 4
HCV Test and Treat Utilizing Simplified HCV Patient Education
NCT04515797Phase 4
QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir
NCT04047680
eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3